Cell line · CVCL_0418
MDA-MB-453
Cancer cell line, Homo sapiens. Breast adenocarcinoma. 114 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. MDA-MB-453. Cell lines, record CVCL_0418. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_0418
On this page
Cell line
As Cellosaurus gives it.
- Name
- MDA-MB-453
- Accession
- CVCL_0418
- RRID
- RRID:CVCL_0418
- Synonyms
- MDA-MB 453, MDA MB 453, MDA-MB453, MDAMB453, MDA-453, MDA453, MD Anderson-Metastatic Breast-453
- Species
- Homo sapiens (Human)
- Sex
- Female
- Age at sampling
- 48Y
- Category
- Cancer cell line
- Diseases
- Breast adenocarcinoma (NCIt C5214)
- Derived from
- Pericardial effusion (metastatic)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers114
2 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| ZBTB1 Regulates Glycolysis and Chemotherapy Resistance Through Interacting with c-Myc in Triple Negative Breast Cancer. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Distinct metabolic dependency on BCAA defines cancer stemness and malignancy in human triple-negative breast cancer. | Cell Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| UBE2L6 promotes invasion and metastasis of triple-negative breast cancer by enhancing autophagy through STK38 ISGylation. | Cell Mol Life Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Molecular Design and Preclinical Evaluation of GenSci143, a Novel B7-H3-Directed and PSMA-Directed Bispecific Antibody-Drug Conjugate, for the Treatment of Prostate Cancer. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Metastasis-Associated Wound Repair Promotes Reciprocal Lung Epithelium Activation and Breast Cancer Metastatic Outgrowth. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| AXL-SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers. | NPJ Precis Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. | Cell | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Discovery of novel circular RNAs of the apoptosis-related BAX gene in breast cancer, by combining nanopore and next-generation sequencing. | Mol Genet Genomics | 2026 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 114
See all 114 papersRelatives4
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | HyCyte MDA-MB-453 KO-hCPB1 | CVCL_F4GL | Cell lines | |
| Derived from it | HyCyte MDA-MB-453 stable cell line for hCPB1 overexpression | CVCL_F4UA | Cell lines | |
| Derived from it | MDA-MB-453 Ad15 | CVCL_ZZ23 | Cell lines | |
| Derived from it | MDA-kb2 | CVCL_6421 | Cell lines |
Cell banks9
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | HTB-131 | ATCC | |
| BCRC | 60429 | BCRC | |
| CLS | 305042 | Discontinued | Cellosaurus |
| DSMZ | ACC-65 | DSMZ | |
| ICLC | HTL01013 | ICLC | |
| IZSLER | BS TCL 247 | Cellosaurus | |
| KCLB | 30131 | KCLB | |
| NCBI_Iran | C214 | Cellosaurus | |
| RCB | RCB1192 | RCB |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0418
GET https://conductscience.org/api/cell-lines/v1/CVCL_0418/papers?page=2